Cytek Biosciences Q4 rev $57.5M (-1.3%); FY24 net loss $6.0M; guides FY25 rev $204-212M

Cytek Biosciences, Inc.

Full year 2024 revenue $200.5M (+3.9% YoY); Q4 revenue $57.5M (-1.3% YoY, +1.4% constant currency).
Net loss improved to $6.0M from $12.1M in 2023; adjusted EBITDA $22.4M (+77% YoY).
Installed base reached 3,034 instruments; 667 placed in 2024.
Board authorized new $50M stock repurchase program for 2025; $21.6M repurchased in 2024.
2025 revenue guidance $204-212M (2-6% growth); opened Singapore manufacturing facility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.